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To  date,  solid organ  and  bone  marrow  transplantation  between genetically 
disparate individuals has depended upon nonspecific immunosuppressive agents 
to control  chronic  rejection.  Although  these agents are vital to suppression  of 
graft rejection, they have their own associated toxicities, including susceptibility 
to opportunistic infections, osteoporosis, impaired hepatic or renal function, and 
an  increased  incidence of neoplasms.  Chronic  rejection,  in  varying degrees of 
severity, often persists despite the use of these agents. 
Numerous  methods  have  been  attempted  to  induce  specific transplantation 
tolerance.  Experimental  animal  models have  included  neonatal  bone  marrow 
inoculation (1) and whole body irradiation,  or fractionated total lymphoid irra- 
diation coincident with bone marrow transplantation and immediate or deferred 
solid organ transplantation  in adult recipients (2-4). As a preparation for subse- 
quent organ allografts, these methods have the advantage of induction of specific, 
rather  than  nonspecific  tolerance.  However,  bone  marrow  transplantation  is 
currently limited by graft-vs.-host disease (GVHD) 1 (5), and a level of immunoin- 
competence probably resulting from failure of appropriate immune cell interac- 
tions  in  the  reconstituted  host  (6-8).  We  have  attempted  to  overcome these 
limitations  in  the  murine  system by reconstituting  the  lethally  irradiated  host 
with  T  cell-depleted  syngeneic plus allogeneic  bone marrow  components (9). 
Such  animals  were  specifically  tolerant  to  donor-type,  full-thickness  tail  skin 
grafts, and exhibited stable hematopoietic chimerism.  In addition, survival rates 
were excellent, with no evidence for GVHD or wasting. 
We have presumed that such mixed reconstituted animals are superior to fully 
allogeneic  chimeras  because  the  presence  of the  syngeneic  components  over- 
comes the  immunoincompetence  that  results  from  restriction  of immune  cell 
interactions  in fully ailogeneic chimeras,  while the allogeneic elements provide 
conditioning for induction of specific tolerance. We have now examined in detail 
patterns  of reconstitution,  immunocompetence,  and  in  vitro reactivity of such 
l Abbreviations used in this paper:  CML.  cell-mediated lympholysis;  Con A, concanavalin A; FITC 
fluorescein isothiocyanate; GVHD, graft-vs.-host disease; MEM, minimum essential medium; MHC, 
major histocompatibility complex; MLR, mixed lymphocyte reaction; MST, median survival time; 
PBL, peripheral blood lymphocyte; PFC, plaque-forming cell; RAMB, rabbit anti-mouse brain; 
SRBC, sheep red blood cell. 
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mixed allogeneically reconstituted animals.  In addition,  we have extended this 
model  to  a  major  histocompatibility  complex  (MHC)-disparate,  noncongenic 
model to assess the  influence of minor antigens on induction and maintenance 
of tolerance to hematopoietic cells and allogeneic tissues.  The mixed allogeneic 
system offers a  model for investigation of mechanisms of induction and mainte- 
nance of transplantation tolerance in the adult animal, with potential application 
to the human clinical setting. 
Materials and Methods 
Animals.  6-8-wk-old male C57BL/10Sn (B10), B10.BR, B10.D2, and C3H/HeJ mice 
were obtained from The Jackson Laboratory, Bar Harbor, ME. Animals were housed in 
a specific pathogen-free facility at the National Institutes of Health. 
Mixed Allogeneic  Reconstitutions  (BIO  +  BIO.D2 --~ BIO).  Mixed allogeneic chimeras 
were prepared by a modification of the methods previously described (10). Briefly, inbred 
B10  male  recipients  were lethally  irradiated  with  950  rad  from a  z37Cs source.  Using 
sterile technique, bone marrow was flushed from the femurs and tibias of B10, B 10.D2, 
B10.BR, and C3H/HeJ male mice with Media 199 (Gibco,  Grand Island, NY) containing 
50 ~l/ml of gentamicin (MEM) using a  23-gauge needle. The marrow was mechanically 
resuspended in MEM by gentle aspiration through a  19-gauge needle, and the suspension 
was sterilely  filtered through nylon mesh. The cells were then centrifuged to a pellet at 
1,200 rpm for  10 min,  resuspended in  MEM,  and counted. Bone marrow was T  cell- 
depleted by treatment with a  1:60 dilution of rabbit anti-mouse brain (RAMB) (at a ratio 
of l0 s cells per milliliter  of RAMB) sera at 4°C for 30 rain,  as previously described (9). 
The  cells  were  subsequently  washed  and  resuspended  in  sterile  filtered  guinea  pig 
complement (Gibco) at a  1:3 dilution in  MEM  (10  s cells/ml)  at 37°C for 30 rain.  Ceils 
were  then  washed  twice  (1,200  rpm  for  10  rain)  and  resuspended  in  MEM  at  the 
concentration appropriate to allow injection of 1 ml final  volume per animal.  Recipient 
animals were reconstituted 4-6  h  after lethal  irradiation via injection  of cells  into the 
lateral  tail  vein,  using a  27  gauge  needle.  Mixed  allogeneically reconstituted  animals 
received 5  X  106 T  cell-depleted syngeneic bone  marrow cells and  1.5  x  10 7  T  cell- 
depleted allogeneic bone marrow cells  unless  otherwise specified.  Such animals will be 
referred to as mixed allogeneic chimeras, mixed allogeneically reconstituted animals,  or 
BI0 +  B10.D2 ~  B10. Fully allogeneically reconstituted mice received 1.5 x  107 T cell- 
depleted  allogeneic bone  marrow  cells  (B10.D2  --~  B10).  Syngeneically reconstituted 
controls received  5  x  10  6  T  cell-depleted syngeneic bone marrow cells (B10  ~  B10). 
Radiation  controls were  performed simultaneously to  confirm adequacy of the  lethal 
radiation dose. 
Assays for Chimerism.  Chimerism of peripheral blood lymphocytes (PBL) was assayed 
using a  trypan  blue  exclusion  microcytotoxicity test  to  determine  the  percentage  of 
lymphocytes bearing host- or donor-type H-2 surface markers as  previously described 
(11).  Briefly,  peripheral  blood was collected into heparinized plastic  serum  vials. After 
thorough mixing, the suspension was diluted with 100 #1 of MEM plus 0.1% gelatin, and 
layered over a cold Ficoll-Hypaque gradient (Bionetics  Laboratory Products, Charleston, 
SC). After centrifugation for 90 s in a  Beckman microfuge, the lymphocyte layer was 
aspirated from the saline-Ficoll  interface, and washed with MEM plus 0.1% gelatin. Red 
blood ceils  were then  ACK-lysed, and  the  remaining cells  were  washed and used  in  a 
trypan blue microcytotoxicity assay. 
Skin  Grafting.  Skin  grafting  was  performed  by  a  modification  of the  method  of 
Billingham (12).  Full-thickness  tail  skin grafts were harvested from the tails of B10.D2, 
B 10.BR, C3H/HeJ, and B10 mice. Mice were anesthetized with tribromoethanol injected 
intraperitoneally  (13),  and  full-thickness  defects  were  created  surgically in  the  lateral 
thoracic wall.  We were careful to preserve  the panniculus carnosum. The grafts were 
covered with a double layer of vaseline  gauze and a plaster cast.  If more than one skin 
graft was placed on an animal, each defect for graft placement was separated by a 3-mm ILDSTAD El"  AL.  233 
skin bridge. Casts were removed on the eighth day. Grafts were scored daily for percent 
rejection, and rejection was considered complete when no residual viable graft was evident. 
Graft survivals were calculated by the life-table method (20), and the median survival time 
(MST) was derived from the time point at which 50% of grafts were surviving. 
Mixed Lymphocyte Reactions (MLR).  MLR were performed as previously described (14). 
Briefly, splenocytes were ACK-lysed, washed, and  reconstituted  in EHAA (NIH Media 
Unit,  Bethesda,  MD) supplemented  with  0.75%  fresh  normal  mouse serum,  0.09  mM 
nonessential amino acids,  1 mM sodium pyruvate, 2 mM glutamine,  I00 U/ml penicillin, 
100  U/ml  streptomycin,  and  0.05  mM  2-mercaptoethanol.  4  x  105  responders  were 
cultured  with  4  x  105  stimulators  (2,000-rad  irradiated  cells)  and  varying numbers of 
cocultured chimeric cells or normal control cells  in a  total  of 200  or 250 #1 of media. 
Cultures were incubated at 37°C, 5% CO~ for 4 d, pulsed on the fourth day with  1 ~Ci 
[3H]thymidine (New England Nuclear, Boston, MA) and harvested on the fifth day with 
an automated harvester (Mash II; Microbiological Associates, Bethesda, MD). 
Cell-mediated Lympholysis (CML).  CML assays were performed using a modification of 
techniques  previously  described  (14,  15).  Briefly,  RPMI  1640  medium  (Gibco)  was 
supplemented  as above, except that  10%  fetal calf serum  (Gibco) was used in place of 
normal  mouse  serum.  4  x  106  responders  were  cocultured  with  4  x  106  stimulators 
(2,000-rad irradiated cells) and 2  x  10  6  or  4  X  106 chimeric putative suppressor cells or 
normal control cells in 2 or 2.5 ml of medium at 37°C for 5 d. Mouse target blasts were 
stimulated with concanavalin A (Con A) (Miles-Yeda Laboratories, Inc., Israel) for 2 d. In 
some  experiments,  tumor  targets  were  used.  After  5  d,  responders  were  harvested, 
counted, and resuspended at appropriate effector/target ratios with 10451Cr-labeled blasts 
as targets. After 4.5 h, supernatants were harvested with the Titertek system, and specific 
lysis  was  calculated  as  follows:  (experimental  release  -  spontaneous  release)  X  100/ 
(maximal  [HCI]  release  -  machine  background).  Spontaneous  release  was  <25%  of 
maximum release unless otherwise indicated. 
Cellular depletions were performed on the chimeric cells to eliminate  H-2  b- or H-2  d- 
bearing cells. Briefly, chimeric cells were incubated with B 10 anti-B 10.D2 sera or B 10.D2 
anti-B10 sera for 15 min at 37°C and 5% CO~ (5 x  106 cells per milliliter of antibody at 
1:20 dilution).  Cells were washed and  resuspended  in screened,  sterilely filtered  rabbit 
complement (5  x  106 cells per milliliter  of complement at  1:8 dilution in MEM) for 30 
min  at  37°C.  The  suspension  was  then  diluted  with  MEM  and  layered  over  warm 
Lympholyte M  (Accurate  Chemical  Scientific Comp.,  Westbury,  NY)  in  50  ml  conical 
tubes, and washed at  1,200 rpm for 25 min to separate viable from nonviable cells. The 
buffy coat was aspirated  and  washed twice in  MEM (1,200  rpm for  10 rain).  The cells 
were then resuspended in media for CML, counted, and the cell density adjusted to the 
appropriate  concentration.  Adequacy  of depletions  was  determined  by  fluorescence- 
activated cell sorter using biotinylinated, protein-purified anti-H-2 b and anti-H-2  d mono- 
clonal antibodies and fluorescein isothiocyanate (FITC)-avidin fluorescent stain as previ- 
ously described (9,  16). 
Plaque-forming Cell (PFC) Assays.  Sheep  red  blood  cell  (SRBC)  PFC  assays  were 
performed as previously described  (17).  Briefly, animals were immunized intravenously 
with 0.2 ml of a  1% sheep red blood cell suspension on day 0. Partial splenectomies were 
performed on day 5, and titrated  numbers of spleen  cells were assayed in triplicate  for 
PFC  responses.  Values  are  expressed  as  plaques  per  10  6  spleen  cells.  All experiments 
reported were recorded by an observer who had no knowledge of the identity of a given 
plate. 
Results 
Survival  of Mice  Reconstituted  with  Fully  AUogeneic (BIO.D2  -~ BIO),  Mixed 
Allogeneic  (BIO  +  BIO.D2  ~  BIO),  and  Syngeneic  (BIO ~  BIO) Bone  Marrow 
Inocula.  Survival  of the  mixed allogeneically reconstituted  mice was excellent. 
Animals  showed  no  evidence  for  GVHD  or  wasting.  However,  in  our  special 
pathogen-free  facility,  long-term  survival  of our  fully  allogeneic  chimeras  was 234  MIXED  ALLOGENEIC  CHIMERAS 
also excellent, and not significantly different from that for syngeneically (B10 ---* 
B10) reconstituted recipients  (Fig.  1).  To further assess in vivo immunocompe- 
tence by means of survival characteristics, age-matched animals from each of the 
following groups were moved from our special facility to a conventional facility 
6  mo after lethal irradiation and bone marrow reconstitution:  (a) syngeneically 
reconstituted  animals  (B10  --*  B10);  (b)  fully  allogeneic  chimeras  (B10.D2  ---* 
B10); and (c) mixed allogeneic  chimeras (B10  +  B10.D2 ~  B10) (Fig.  2).  50-d 
survival after relocation  was 40%  for fully allogeneic  chimeras,  80%  for mixed 
allogeneic  chimeras,  and 83%  for syngeneically  reconstituted  mice.  Three  rep- 
resentative  mice  that  died  were  sent  for  serologic  testing  and animal  autopsy, 
and  were  found to  have died  from  endemic  viral  infections,  including  mouse 
20 
RECONSTITUTION  n 
H  Mixed AIIogeneic  37 
H  Fully  AFIogeneic  30 
C)~-O Syngeneic  30 
20  aO  2~  220  380 
DAYS POST RECONSTITUTION 
FIGURE  1.  Survival of mixed  allogeneic  chimeras  (B10  +  B10.D2 ---* B10),  fully allogeneic 
chimeras  (B10.D2 ~  B10) and  syngeneically  reconstituted  mice  (B10 ~  BI0) in our specific 
pathogen-free  facility, as calculated  by the life table method.  Minimum  follow-up was 79 d. 
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FIGURE  2.  Survival  of mice  reconstituted  with  mixed  allogeneic  (B10  +  B10.D2  ---* BI0), 
fully allogeneic  (B10.D2  ~  B10),  or  syngeneic (B10  ~  B10)  bone  marrow  inoculum in  a 
conventional  facility.  Mice  were moved  to a conventional  facility 6  mo after lethal irradiation 
and  reconstitution;  before  this  they  had  been  housed  in  a  specific  pathogen-free  facility. 
Survivals  were calculated  by the  life table method.  Animals  were  followed  for a  minimum  of 
90 d  postrelocation. ILDSTAD  ET  AL.  235 
hepatitis  virus  and  Sendal  virus.  In  addition,  Citrobacter freundii  was  isolated 
from the intestines of those animals. 
lmmunocompetence as Assessed by PFC Responses and Hemagglutination Assay.  In 
an attempt to further assess in vivo immunocompetence  of the mixed ailogeneic 
chimeras  (B10  +  B10.D2  --~  B10),  animals  were  subjected  to  intravenous  im- 
munization  with  SRBC  suspensions,  and  their  ability  to  form  primary  PFC 
responses quantitated.  Mixed allogeneically reconstituted animals were found to 
be  immunocompetent,  with  PFC  responses  similar  to  those  of  syngeneically 
reconstituted  (B10  ~  B10)  mice.  As  seen  in  Fig.  3,  fully  allogeneic  chimeras 
B 10.D2 ~  B 10) responded less well. These data suggest that the mixed allogeneic 
chimeras are able to recognize foreign antigens in the context of self. 
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FIGURE 3.  Immunocompetence as assessed by primary PFC responses to in vivo immuniza- 
tion with SRBC. Responses are expressed  as the geometric mean of plaques  per 10  6 spleen 
cells ~ SEM. Syngeneic (B10 ---* B10) (n =  9), mixed allogeneic chimeras (B10 + B10.D2 
B10) (n =  10), and fully allogeneic  chimeras  (B10.D2 ~  B10) (n =  8) were tested.  Normal 
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Hematopoietic  Repopulation.  PBL  typing  of the  mixed  allogeneically  reconsti- 
tuted animals by trypan blue exclusion microcytotoxicity assay revealed variable 
percentages  of donor-type  lymphoid  cells.  Percentages  of ailogeneic  lymphoid 
elements ranged from 5%  to 95%  in peripheral  blood.  However, in all animals, 
donor-type elements  were  identified.  The  time  course  of reconstitution  of five 
fully allogeneic and five mixed allogeneic  chimeras was followed serially  (Table 
I). Although the absolute percentages of donor-type lymphoid elements was seen 
to fluctuate over time,  the animals all remained  chimeric. 
Specific  Tolerance  to Donor-type  Lymphoid Elements  as Evidenced  by MLR.  As 
seen  in  a  representative  one-way  MLR  (Table  II),  mixed  allogeneic  chimeric 
responding  ceils  (B10  +  BI0.D2  ~  B10)  were  specifically  unreactive  to donor 
(B10.D2) and  host-type (B10) stimulator  cells,  while  the response to third-party 
(B10.BR) cells was intact. 
The  response of normal control B10 lymphocytes against B10.D2 splenocytes 
in coculture with chimeric cells has revealed no evidence for specific or nonspe- 
cific  suppression  from  3  wk  to  >1  yr  after  mixed  allogeneic  reconstitution. 
Experiments  included  titration  of increasing  numbers  of cocultured  chimeric 
cells with 4  X  105 normal B 10 lymphoid cells responding to B 10.D2 stimulators, 
as well as addition  of chimeric cells to the reciprocal B 10.D2 anti-B 10 response. 
Specific  Tolerance  to Allogeneic  Donor-type  Lymphoid  Elements  as Evidenced  by 
CML.  Cells  from the  spleens  of mixed allogeneic  chimeras  (B10  +  B10.D2 
B10)  were  examined  for  in  vitro  CML  sensitization  against  B10,  B10.D2,  or 
TABLE  I 
Characterization of Reconstitution of FuUy Allogeneic and Mixed Allogeneic Chimeras 
Reconstitution  Animal number 
BI 0.D2 cells* at various weeks 
after reconstitution: 
1  2  3  5  48 
Fully allogeneic (B10.D2 --* B10) 
Mixed allogeneic (B10 + B10.D2 -* B10) 
% 
Normal B10  1  0  0  2 
Normal BI0.D2  99  100  96  98  99 
637  69  93  74  78  100 
638  80  100  100  78  100 
639  78  100  71  NT*  NT 
640  81  100  100  79  92 
64l  84  96  100  100  100 
626  68  70  67  88  62 
627  71  72  80  61  84 
628  74  12  11  53  86 
629  68  90  84  82  100 
630  73  62  73  NT  NT 
Complement-mediated cytotoxicity was performed on PBL by trypan blue exclusion microcytotox- 
icity assay. 
* Percentage of B10.D2 was calculated  by normalizing the total  percent  specific kill by the two 
antisera  used (anti-H-2 b and anti-H-2 d) to 100%, after correction for percent lysis by complement 
(C) alone: [(percent  B10.D2 -  C)/(percent B10.D2 + percent B10) -  2(C)] x  100. 
* Animal not tested  because of death or sacrifice. ILDSTAD  ET  AL  237 
TABLE  II 
Host Hyporeactivity and Third-party Reactivity of Mixed Allogeneically Reconstituted Animals 
in One-way MLR (BIO + BIO.D2 --) BIO) 
Animal 
[SH]Thymidine uptake 
Anti-B 10  Anti-B 10. D2  Anti-B 10.BR 
cpm 
Normal B10  4,877 +  408  31,584 +  2,433  34,800 -+ 2,921 
Normal B10.D2  22,788 +  888  2,763 +  267  19,724 _  729 
Chimera A  3,347 "4" 237  3,197 +  435  14,762 -+ 303 
Chimera B  2,725 +  292  2,427 +  456  11,600 +- 250 
Stimulation index 
Anti-B 10.D2  Anti-B 10.BR 
Normal BI0  6.5  7.1 
Normal BI0.D2  8.3  7.1 
Chimera A  0.9  4.3 
Chimera B  0.9  4.5 
Mean +  SEM of triplicate cultures at 1 : 1 responder/stimulator ratio. Representative MLR illustrating 
the responses of two individual animals. There was little animal-to-animal variation. 
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F~C,  URE  4.  Skin allograft survival in mixed allogeneic chimeras, as calculated by the life table 
method. Skin grafts were followed for a  minimum of 94 d. 
B10.BR stimulator  cells in  one-way CML.  Corresponding  cultures of chimeric 
responding  cells produced no detectable cytotoxic effectors for host (B10)- or 
donor  (B10.D2)-type  Con  A  blast  targets,  but  produced  effectors  capable  of 
lysing B10.BR third-party blasts with an efficiency similar to that of nonirradiated 
control B 10 and B 10.D2 responders. In addition, chimeric lymphoid populations 
depleted of either  H-2  b- or H-2d-bearing cells were specifically tolerant to host- 
and donor-type stimulator  cells, but normally reactive to third-party  cells (Fig. 
4). To test for the possibility of active suppression, normal B 10 responding cells 
were cocultured  with  unirradiated  spleen cells from chimeras,  and  B10.D2 or 
third-party B 10.BR stimulators. In these experiments, no suppression of the B 10 
anti-B10.D2  response  nor  the  B10  anti-B10.BR  response  could  be  detected, 
offering no evidence for specific or nonspecific suppression. 238  MIXED ALLOGENE1C CHIMERAS 
Specific Tolerance to Allogeneic Donor-strain Skin Grafts in MHC-congenic Mixed 
Allogeneic Chimeras.  Consistent with our previous findings (9), mixed allogene- 
ically reconstituted mice (B 10 +  B 10.D2 ~  B 10) demonstrated specific tolerance 
to  donor-type  B10.D2  full-thickness  tail  skin  grafts  (MST  >380  d)  (Fig.  5). 
Rejection of third-party allografts followed a  time course similar to normal B10 
mice and syngeneically (B 10 ~  B 10) reconstituted recipients (MST =  14 d). All 
retained  grafts  were  soft  and  appeared  healthy,  without  evidence of chronic 
rejection or inflammation, and they persisted in situ without contraction for the 
life span  of the  animal.  These findings  were also extended  to another  mixed- 
MHC  congenic  combination  (B10  +  B10.BR  ~  BI0),  which  likewise  showed 
mixed chimerism and tolerence (Table III). 
Assessment of  MHC-noncongenic  Mixed Allogeneic Model; Skin Grafting, Chimerism, 
and Serologic Reactivity.  To assess  whether  such  complete acceptance of skin 
grafts  could  be  achieved  in  strains  differing  in  both  MHC  and  background, 
mixed allogeneic chimeras (B 10 +  C3H/HeJ ~  B 10) were produced, and grafted 
with  allogeneic  donor-type  (C3H;  H-2  k)  and  third-party  (B10.D2;  H-2  d)  skin 
grafts. In these animals, third-party skin grafts were rejected with a  time course 
similar to unirradiated controls. The donor-type skin grafts were accepted, and 
initially appeared soft and healthy; however, after -30  d the onset of induration 
was  noted,  and  the  grafts  then  followed  a  course  consistent  with  prolonged 
chronic rejection. All grafts eventually contracted in size, and were considered 
rejected by 90 d  (MST =  66 d) (Table III). Sera from two separate bleeds, taken 
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FIGURE 5.  Representative experiment  of specific cytotoxic T  lymphocyte lysis by mixed 
allogeneic chimeric splenocytes of CrS]-labeled target cells in one way CML to host, donor, 
and third-party targets. Spontaneous release was <25%  unless otherwise indicated. B10 + 
B10.D2 --* B10  spleen cells were untreated  (["l--U]), depleted  of H-2  b- (11-----,), or H-2  d- 
([-I--[]) bearing cells by specific sera and tested in the assays. Efficacy of cellular depletions 
were confirmed by fluorescence-activated cell sorter using biotinylated protein-purified anti- 
H-2  b and anti-H-2  a monoc[onal antibodies and FITC-avidin fluorescent stain. ILDSTAD  ET  AL. 
TABLE  III 
Skin Graft Acceptance in MHC-congenic and MHC and Minor Disparate Strains 
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Reconstitution 
Skin graft survival 
Animal  Third 
num-  Donor  party* 
ber  strain skin  skin 
graft  graft 
Median survival 
time 
Third 
Donor 
party 
Mixed allogeneic 
MHC-congenic (BI0 +  B10.BR --~ B10) 
Mixed allogeneic 
MHC-congenic (B10 +  BI0.D2 --, B10) 
Mixed allogeneic (B10 +  C3H --* B10) 
1  149*  14  >149 
2  149'  23 
3  149  ~  19 
4  >250  14  >250 
5  >250  19 
6  >250  23 
7  >250  19 
8  66  19  66 
9  66  23 
10  88  23 
11  59  14 
12  90  11 
13  TF  11 
14  40  11 
15  88  11 
19 
19 
12.5 
* Third party was congenic B10.D2 or B10.BR. 
* Animal was sacrificed for in vitro cellular assays. 
death. 
Graft survival is recorded as intact up to date of 
from the animals  at the time of most severe graft  inflammation  and  rejection 
were not cytotoxic for C3H or B10.BR (H-2  k) target spleen cells by trypan blue 
cytotoxicity assay (data not shown). On day 70, these same animals were grafted 
with  B10.BR skin  grafts  in  order  to  assess the  status  of anti-MHC  immunity. 
Such  MHC-disparate  congenic  allografts  were  accepted,  and  have  remained 
intact without evidence of acute or chronic inflammation for longer than  100 d. 
PBL  typing  of MHC-noncongenic  allogeneic  chimeras  was  carried  out  by 
trypan blue microcytotoxicity assay before the onset of chronic rejection of skin 
allografts,  and at the height  of the chronic rejection,  or after rejection (Table 
IV). Although the percentages of C3H allogeneic cells detectable fluctuated, all 
animals remained mixed chimeras despite rejection of C3H skin grafts. 
Discussion 
Numerous studies (8,  18,  19) have demonstrated  that  elimination  of mature 
T  cells from donor bone marrow inocula can lead to long-term survival of fully 
allogeneic radiation  bone marrow  chimeras  in  specific pathogen-free  facilities. 
However,  the  survival  of  such  animals  is  generally  not  as  good  as  that  of 
syngeneically  reconstituted  controls,  and  the  health  of the  animals  is  often 
compromised, probably as a  result of immunoincompetence due to a  failure of 
appropriate  immune  cell  interactions  (6-8).  These  observations are  especially 
true for animals housed in conventional facilities (6, 7), where survival has been 
reported to be very poor. In vitro studies of restriction by Singer et al. (8) have 240  MIXED  ALLOGENEIC  CHIMERAS 
TABLE  IV 
Characterization of MHC-disparate Congenic and Noncongenic Mixed Allogeneic Chimeras 
111 d after  141 d after 
reconstitution  reconstitution 
Animal  H-2  k or  Donor  H-2  k or H-2  d  Donor  Reconstitution  number  H-2  d do-  skin  skin 
donor-type 
nor-type  graft  cells*  graft 
cells*  status*  status* 
Normal BIO 
%  % 
1  0 
Normal C3H  99  99 
Mixed allogeneic  l  5  on  1  on 
MHC-congenic  2  l l  on  73 (very  on 
(B10 + B10.BR ---, Bt0)  few cells) 
3  NT  on  28  on 
(B10 + B10.D2 ~  B10)  4  64  on  25  on 
5  5  on  31  on 
6  74  on  70  on 
7  61  on  38  on 
8  27  on  63  off 
8  23  on  43  off 
10  44  on  42  on 
11  48  on  63  off 
12  85  on  91  on 
13  20  TF  §  53  TF 
14  49  on  63  off 
15  44  on  50  on 
Mixed allogeneic MHC-noncon- 
genic (B10 + C3H ~  B10) 
* Percent H-2k-bearing lymphoid cells was calculated by normalizing the total percent specific kill by 
the  two  antisera used  (anti-H-2  h and anti-H-2  k) to  100%  after correction  for percent  lysis by 
complement (C) alone. [(Percent H-2  k -  C)/(%  H-2  k +  % H-2  b) -  2(C)]  ×  100.  Percent H-2  a- 
bearing allogeneic donor-type cells was calculated in a similar fashion for animals 4-7. 
* Animals were grafted 90 d after lethal irradiation and reconstitution with allogeneic donor-strain 
skin identical to bone marrow transplant. 
TF, technical failure. 
demonstrated  that  lymphocytes  from  fully allogeneic  chimeras  are  competent, 
but are apparently  restricted to interacting with accessory cells that express host, 
but not donor,  MHC  determinants.  In these studies, intact spleen cells from such 
chimeras  were  not  capable  of generating  responses  to  trinitrophenol-keyhole 
limpet hemocyanin  (TNP-KLH)  unless accessory  cells of host  type  were  added 
to  in  vitro  cultures,  supporting  the  hypothesis  that  the  immunoincompetence 
may be due to a  failure of appropriate  immune  cell interactions in these animals. 
These  limitations  may  be  overcome  by  reconstituting  the  murine  recipient 
with a  mixture  of syngeneic plus allogeneic bone  marrow  (8, 9).  We hypothesize 
that  the  aliogeneic  lymphoid  component  provides  a  milieu  for  induction  of 
specific  transplantation  tolerance  to  the  donor  strain,  while  the  presence  of 
syngeneic lymphoid  elements  abrogates  the limitations of immunoincompetence 
observed  in fully allogeneic chimeras  in vivo and in vitro. ILDSTAD ET AL.  241 
The mixed allogeneically reconstituted mice (B10  +  B10.D2  ~  B10)  were 
found to be immunocompetent in B cell and helper T  cell function, as assessed 
by primary PFC responses to in vivo SRBC immunization. Their responses did 
not differ significantly from those of syngeneically (B10 ~  B10) reconstituted 
mice. This was in contrast to fully allogeneic chimeras, the majority of which did 
not respond. Further evidence for the immunocompetence of such mixed allo- 
geneic chimeras is provided by their superior survival in a conventional animal 
facility in  comparison  with  fully allogeneic chimeras,  the  majority of which 
succumbed to endemic viral infections. 
The mixed allogeneically reconstituted mice (B 10 + B 10.D2 ~  B 10) represent 
true mixed chimeras, bearing variable percentages of syngeneic and allogeneic 
lymphoid elements in  their peripheral blood.  Such chimerism has been main- 
tained for >48  wk after bone  marrow transplantation.  These findings are in 
contrast with our model for mixed xenogeneic reconstitution (B10 +  F344 rat 
B10), where only low levels, if any, of donor-type lymphoid elements could 
be identified, despite acceptance of donor-type skin xenografts and specific in 
vitro tolerance to xenogeneic donor strain by MLR and CML (20). In addition, 
the percentage of allogeneic dohor-strain cells present in such mixed allogeneic 
chimeras did  not appear  to  have an  influence on  the degree of tolerance to 
donor strain, as evidenced by specific skin graft acceptance and in vitro responses 
in CML and MLR. 
Despite reconstitution of the host with three times more allogeneic T  cell- 
depleted bone marrow cells than identically treated syngeneic cells in the mixed 
allogeneic model, the animals manifested a variable range of mixed chimerism. 
The proportion of allogeneic donor-type (B10.D2) cells ranged from 5% to 95% 
in individual animals. 
In  contrast  with  MHC-congenic  mixed  allogeneic  chimeras,  in  which  the 
allogeneic (B10.D2,  B10.BR)  donor-strain  skin allografts  were specifically ac- 
cepted  indefinitely,  without  evidence for  chronic  rejection  donor-strain  skin 
allografts from MHC-noncongenic mixed allogeneic chimeras (B10  +  C3H --~ 
B 10) underwent a chronic rejection reaction, with ultimate disappearance of the 
donor-type (C3H) skin graft. However, allogeneic donor-strain (C3H) lymphoid 
elements persisted  in  the hematopoietic system, despite rejection of the C3H 
skin grafts, and sera taken from the animals during the rejection process were 
not cytotoxic for C3H  splenocytes. In addition,  B10.BR  skin grafts placed on 
those animals after rejection of the C3H (H-2  k) grafts were accepted indefinitely, 
without evidence of inflammation. This disparity of response to hematopoietic 
elements vs. skin allografts is most likely due to skin-specific alloantigens, perhaps 
similar to those characterized by Boyse et al. (21) and Steinmuller et al. (22).  If 
so, subsequent survival of B 10.BR allografts indicates that such alloantigens must 
be encoded by genes outside the MHC.  The appearance of prolonged chronic 
rejection with eventual slow contraction of the skin allografts and,  ultimately, 
rejection, is reminiscent of the results we reported (20) in the mixed xenogeneic 
system (B10 +  F344 rat ~  B10), suggesting that the ultimate rejection of skin 
grafts in this model may also have been due to skin-specific antigens. Studies are 
currently in progress to assess the in vitro reactivity of these MHC-noncongenic 
mixed allogeneic chimeras. 242  MIXED  ALLOGENEIC  CHIMERAS 
Rejection of noncongenic skin grafts does not necessarily imply a problem for 
the adaptation  of this  model  to  transplantation  of vascularized organs,  since 
mismatching for non-MHC antigens does not appear to be of great significance 
for the outcome of renal allografts in man (23). In addition, skin-specific alloan- 
tigens may be among the few minor transplantation antigens not also expressed 
on bone marrow cells. In this regard, Steinmuller and Lofgreen (22) reported 
acceptance of cardiac allografts in radiation bone marrow chimeras despite the 
rejection of donor-type skin grafts. Skin may indeed be the most difficult aliograft 
to prolong, and studies of vascularized grafts in this model are now in progress. 
Mixed allogeneic reconstitution may provide a model for investigation of the 
mechanisms of induction and  maintenance of specific tolerance to  allogeneic 
lymphoid elements. In addition,  it  may offer applications  to the clinical bone 
marrow and solid organ transplantation setting. Conditioning of the host with 
single high-dose irradiation (or perhaps other suppressive regimens) and imme- 
diate mixed allogeneic bone marrow reconstitution coincident with solid organ 
transplantation could afford immediate use of donor organs with the potential 
for acceptance of the donor allograft in the absence of prolonged nonspecific 
chemical immunosuppressive agents. One major advantage of such mixed bone 
marrow reconstitution would be the ability to overcome the immunoincompe- 
tence observed  in  fully allogeneic chimeras,  while  inducing and  maintaining 
specific  tolerance to  the  donor.  Attempts  to  extend  these  studies  to  a  large 
animal model are now progress. 
Summary 
Mixed allogeneically reconstituted mice (B 10 +  B10.D2 --* B 10) that specifi- 
cally accept B10.D2  tail skin atlografts were examined for in vivo and in vitro 
immunocompetence, patterns of hematopoietic repopulation, and in vitro reac- 
tivity. In vitro, mixed allogeneic chimeras (B10 +  B10.D2 ~  B10) manifested 
specific tolerance in mixed lymphocyte reactions and cell-mediated lympholysis 
to B10 and B10.D2 splenocytes, with normal responses to third-party (B10.BR) 
cells. Such chimeras were immunocompetent in B cell and helper T cell responses, 
as assessed by their primary plaque forming cell responses to in vivo sheep red 
blood cell immunization. This is in contrast to fully altogeneic chimeras, which 
responded less well. In addition, survival of the mixed allogeneic chimeras in a 
conventional animal facility was superior to that of fully allogeneic chimeras, and 
similar to syngeneically reconstituted (B10 --* B10) mice. Specific tolerance to 
skin grafts, degree of allogeneic engraftment, and persistence of chimerism was 
also assessed in  a  noncongenic mixed allogeneic combination (B10  +  C3H 
B 10). Such animals manifested specific hyporeactivity to C3H skin allografts, but 
eventual chronic rejection of the grafts occurred in spite of stable and persistent 
mixed chimerism. MHC-congenic (B 10.BR) skin grafts were accepted indefinitely 
in the same animals, suggesting that skin-specific non-major histocompatibility 
complex antigens were responsible for rejection of the C3H skin allografts. 
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